Liraglutide
Saxenda
Daily GLP-1 agonist.
Mechanism of Action
GLP-1 receptor agonist.
Key Benefits
- 8% average weight loss
Common Uses
What to Expect
Onset
Appetite reduction within 24–48 hours of first dose; weight loss visible within 2–4 weeks
Duration
Effects last ~24 hours per injection (daily dosing); weight loss progressive over months
What Users Report
- Steady, reliable appetite suppression that's consistent day-to-day with daily dosing
- Less dramatic appetite reduction compared to semaglutide, but more consistent and predictable
- GI side effects (nausea, bloating) during titration, typically milder than weekly injectables
- Progressive, steady weight loss — typically around 8% of body weight over 6–12 months
- Some users prefer the daily dosing because it provides more even, predictable appetite control
- Improved blood sugar control and reduced sugar cravings
- A more gradual transition to smaller portions; less of the dramatic 'food noise' elimination seen with semaglutide
Typical Timeline
Days 1–3: Appetite suppression begins. Weeks 1–4: Titration phase — gradually increasing dose while GI side effects are managed. Weeks 4–8: Steady weight loss establishes; typically 0.5–1 lb/week. Months 2–6: Progressive weight loss continues; ~8% total body weight reduction on average. Ongoing: Sustained weight management with continued daily use.
Side Effects
- GI upset
Dosage Protocol
Start 0.6 mg daily subcutaneously, titrate to 3 mg. Cycles: Continuous.
Always consult a physician before starting any peptide protocol.
Administration
Injection
FDA Status
FDA-approved
Stacks Well With
- CJC-1295/Ipamorelin
Tags
Related peptides
Ipamorelin
Selective ghrelin mimetic – safest GH peptide.
CJC-1295 (with/without DAC)
Growth Hormone Releasing Hormone analog
Long-acting GH secretagogue.
Semaglutide
GLP-1 agonist
FDA-approved weight-loss powerhouse.
Tirzepatide
Dual GIP/GLP-1 agonist
Next-gen dual agonist (Mounjaro/Zepbound).